» Articles » PMID: 30968054

Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic

Overview
Date 2019 Apr 11
PMID 30968054
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Steatosis contributes to liver fibrosis in hepatitis C virus (HCV) and human immunodeficiency virus (HIV)/HCV coinfection. Liver biopsy (LB) is the reference standard for grading steatosis and staging fibrosis, yet recent advances in noninvasive modalities have largely supplanted LB, which may limit recognition of steatosis. We evaluated steatosis rates by LB and transient elastography (TE) with controlled attenuation parameter (CAP) among HCV-infected and HIV/HCV-coinfected patients in a US clinic.

Methods: Patients with chronic HCV infection during pretreatment evaluation by LB (n = 421; December 2001 through May 2014) and TE with CAP (n = 1157; May 2016 through May 2017) were included. Fibrosis and steatosis rates by LB and TE with CAP were stratified by HCV versus HIV/HCV coinfection status.

Results: Steatosis was not reported in 26.1% of LBs. Moderate to severe steatosis (grade ≥S2) was detected more often with CAP than with LB (in 24.0% vs 11.4% of patients, respectively). Median CAP values were higher in patients with HCV monoinfection than in those with coinfection (230 vs 215.5 dB/m, respectively; < .001). With TE, the rate of advanced fibrosis (values F3-F4) was higher in HCV monoinfection than in coinfection (25.9% vs 14.8%, respectively; <.001). With both LB and TE, advanced fibrosis (F3-F4) was significantly associated with moderate to severe steatosis (S2-S3) in HCV monoinfection compared with HIV/HCV coinfection (33.3% vs 4.4%, respectively for LB [ = 0.003] and 36.0% vs 29.0% for TE [ = 0.008]).

Conclusions: In patients with chronic HCV undergoing liver fibrosis staging, steatosis was detected more often with CAP than LB, with median CAP values higher in HCV monoinfection than HIV/HCV coinfection. Steatosis severity may be increasing in the modern HCV treatment era.

Citing Articles

The effects of intermittent fasting diet in comparison with low-calorie diet on lipid profile, glycemic status, and liver fibrosis in patients with non-alcoholic fatty liver (NAFLD): a study protocol for a randomized controlled clinical trial.

Karimi M, Mofidi Nejad M, Akhgarjand C, Sohrabpour A, Poustchi H, Imani H BMC Nutr. 2023; 9(1):145.

PMID: 38066628 PMC: 10704665. DOI: 10.1186/s40795-023-00794-x.


Nonalcoholic fatty liver disease and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.

Karjoo S, Auriemma A, Fraker T, Bays H Obes Pillars. 2023; 3:100027.

PMID: 37990727 PMC: 10661876. DOI: 10.1016/j.obpill.2022.100027.


Evaluating M2BPGi as a Marker for Liver Fibrosis in Patients with Chronic Hepatitis B.

Bui H, Nguyen S, Phan S, Nguyen K, Nguyen C Dig Dis Sci. 2023; 68(12):4407-4417.

PMID: 37861877 PMC: 10635958. DOI: 10.1007/s10620-023-08143-5.


Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan.

Ersoy Yesil E, Yilmaz Y, Yesil A, Mese M, Kaya E, Bakir E Hepatol Forum. 2023; 4(1):14-18.

PMID: 36843889 PMC: 9951894. DOI: 10.14744/hf.2022.2022.0038.


Diagnostic Performance of Acoustic Radiation Force Impulse Imaging in Evaluating Liver Fibrosis in Patients with Chronic Hepatitis B Infection: A Cross-Sectional Study.

Bui H, Vo V, Nguyen C, Phan S, Quach P, Nguyen D Indian J Radiol Imaging. 2022; 32(3):287-293.

PMID: 36177272 PMC: 9514909. DOI: 10.1055/s-0042-1755251.


References
1.
Brunt E, Janney C, Di Bisceglie A, Neuschwander-Tetri B, Bacon B . Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999; 94(9):2467-74. DOI: 10.1111/j.1572-0241.1999.01377.x. View

2.
Sherman K, Rouster S, Chung R, Rajicic N . Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002; 34(6):831-7. DOI: 10.1086/339042. View

3.
Castera L, Hezode C, Roudot-Thoraval F, Bastie A, Zafrani E, Pawlotsky J . Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut. 2003; 52(2):288-92. PMC: 1774979. DOI: 10.1136/gut.52.2.288. View

4.
Sulkowski M, Thomas D . Hepatitis C in the HIV-infected patient. Clin Liver Dis. 2003; 7(1):179-94. DOI: 10.1016/s1089-3261(02)00074-0. View

5.
Wai C, Greenson J, Fontana R, Kalbfleisch J, Marrero J, Conjeevaram H . A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 38(2):518-26. DOI: 10.1053/jhep.2003.50346. View